Sanofi SA (SAN) PT Set at €88.00 by Citigroup Inc.
Sanofi SA (EPA:SAN) has been assigned a €88.00 ($103.53) target price by equities researchers at Citigroup Inc. in a research report issued on Friday. The brokerage presently has a “neutral” rating on the stock.
SAN has been the subject of several other research reports. Morgan Stanley set a €92.00 ($108.24) target price on Sanofi SA and gave the company a “buy” rating in a research note on Friday. S&P Global set a €90.00 ($105.88) target price on Sanofi SA and gave the company a “neutral” rating in a research note on Monday, July 31st. J P Morgan Chase & Co set a €90.00 ($105.88) target price on Sanofi SA and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Jefferies Group LLC set a €90.00 ($105.88) target price on Sanofi SA and gave the company a “neutral” rating in a research note on Friday, June 16th. Finally, BNP Paribas set a €85.00 ($100.00) target price on Sanofi SA and gave the company a “neutral” rating in a research note on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have issued a buy rating to the company’s stock. Sanofi SA has a consensus rating of “Hold” and a consensus price target of €87.88 ($103.39).
Shares of Sanofi SA (SAN) opened at 86.26 on Friday. The stock has a market capitalization of €108.32 billion and a price-to-earnings ratio of 12.03. The company has a 50 day moving average of €26.12 and a 200 day moving average of €26.01. Sanofi SA has a 52-week low of €24.55 and a 52-week high of €86.26.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with Analyst Ratings Network's FREE daily email newsletter.